S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NYSE:IQV

IQVIA Stock Competitors

$261.61
-0.66 (-0.25 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$259.04
$263.52
50-Day Range
$241.69
$265.23
52-Week Range
$146.03
$265.34
Volume715,114 shs
Average Volume895,572 shs
Market Capitalization$50.13 billion
P/E Ratio83.85
Dividend YieldN/A
Beta1.42

IQVIA (NYSE:IQV) Vs. CRL, EXAS, PPD, INCY, ICLR, and SYNH

Should you be buying IQVIA stock or one of its competitors? The main competitors of IQVIA include Charles River Laboratories International (CRL), Exact Sciences (EXAS), PPD (PPD), Incyte (INCY), ICON Public (ICLR), and Syneos Health (SYNH). These companies are all part of the "commercial physical research" industry.

Charles River Laboratories International (NYSE:CRL) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Volatility & Risk

Charles River Laboratories International has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Institutional and Insider Ownership

93.3% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 87.0% of IQVIA shares are owned by institutional investors. 1.2% of Charles River Laboratories International shares are owned by insiders. Comparatively, 1.1% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Charles River Laboratories International and IQVIA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories International12.10%23.59%8.66%
IQVIA4.69%23.95%6.03%

Earnings & Valuation

This table compares Charles River Laboratories International and IQVIA's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$2.92 billion7.90$364.30 million$8.1356.37
IQVIA$11.36 billion4.41$279 million$6.0343.38

Charles River Laboratories International has higher earnings, but lower revenue than IQVIA. IQVIA is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Charles River Laboratories International and IQVIA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International03902.75
IQVIA011502.94

Charles River Laboratories International currently has a consensus price target of $399.8333, suggesting a potential downside of 12.76%. IQVIA has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. Given IQVIA's stronger consensus rating and higher probable upside, analysts plainly believe IQVIA is more favorable than Charles River Laboratories International.

Exact Sciences (NASDAQ:EXAS) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings & Valuation

This table compares Exact Sciences and IQVIA's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exact Sciences$1.49 billion11.07$-848,530,000.00($1.38)-69.58
IQVIA$11.36 billion4.41$279 million$6.0343.38

IQVIA has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Exact Sciences and IQVIA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Exact Sciences-50.52%-8.93%-4.86%
IQVIA4.69%23.95%6.03%

Volatility & Risk

Exact Sciences has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Institutional and Insider Ownership

88.3% of Exact Sciences shares are owned by institutional investors. Comparatively, 87.0% of IQVIA shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by insiders. Comparatively, 1.1% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Exact Sciences and IQVIA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Exact Sciences031212.88
IQVIA011502.94

Exact Sciences currently has a consensus price target of $151.0625, suggesting a potential upside of 57.32%. IQVIA has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. Given Exact Sciences' higher probable upside, equities analysts plainly believe Exact Sciences is more favorable than IQVIA.

Summary

IQVIA beats Exact Sciences on 10 of the 15 factors compared between the two stocks.

IQVIA (NYSE:IQV) and PPD (NASDAQ:PPD) are both large-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares IQVIA and PPD's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQVIA$11.36 billion4.41$279 million$6.0343.38
PPD$4.68 billion3.52$153.69 million$1.1341.46

IQVIA has higher revenue and earnings than PPD. PPD is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IQVIA and PPD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IQVIA4.69%23.95%6.03%
PPD3.85%-53.95%6.08%

Risk & Volatility

IQVIA has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, PPD has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of IQVIA shares are owned by institutional investors. Comparatively, 87.9% of PPD shares are owned by institutional investors. 1.1% of IQVIA shares are owned by company insiders. Comparatively, 1.9% of PPD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for IQVIA and PPD, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IQVIA011502.94
PPD010302.23

IQVIA currently has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. PPD has a consensus price target of $44.5625, suggesting a potential downside of 4.88%. Given IQVIA's stronger consensus rating and higher possible upside, research analysts plainly believe IQVIA is more favorable than PPD.

Summary

IQVIA beats PPD on 10 of the 14 factors compared between the two stocks.

IQVIA (NYSE:IQV) and Incyte (NASDAQ:INCY) are both large-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares IQVIA and Incyte's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQVIA$11.36 billion4.41$279 million$6.0343.38
Incyte$2.67 billion5.71$-295,700,000.00($1.06)-65.09

IQVIA has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IQVIA and Incyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IQVIA4.69%23.95%6.03%
Incyte12.41%15.77%11.66%

Risk & Volatility

IQVIA has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of IQVIA shares are owned by institutional investors. Comparatively, 92.0% of Incyte shares are owned by institutional investors. 1.1% of IQVIA shares are owned by company insiders. Comparatively, 15.8% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for IQVIA and Incyte, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IQVIA011502.94
Incyte13602.50

IQVIA currently has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. Incyte has a consensus price target of $95.3750, suggesting a potential upside of 38.22%. Given Incyte's higher possible upside, analysts plainly believe Incyte is more favorable than IQVIA.

Summary

IQVIA beats Incyte on 8 of the 14 factors compared between the two stocks.

IQVIA (NYSE:IQV) and ICON Public (NASDAQ:ICLR) are both large-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares IQVIA and ICON Public's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQVIA$11.36 billion4.41$279 million$6.0343.38
ICON Public$2.80 billion5.35$332.33 million$6.5343.34

ICON Public has lower revenue, but higher earnings than IQVIA. ICON Public is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IQVIA and ICON Public's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IQVIA4.69%23.95%6.03%
ICON Public11.40%22.10%12.27%

Risk & Volatility

IQVIA has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, ICON Public has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of IQVIA shares are owned by institutional investors. 1.1% of IQVIA shares are owned by company insiders. Comparatively, 44.0% of ICON Public shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for IQVIA and ICON Public, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IQVIA011502.94
ICON Public03802.73

IQVIA currently has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. ICON Public has a consensus price target of $254.50, suggesting a potential downside of 10.08%. Given IQVIA's stronger consensus rating and higher possible upside, research analysts plainly believe IQVIA is more favorable than ICON Public.

Summary

IQVIA beats ICON Public on 8 of the 14 factors compared between the two stocks.

IQVIA (NYSE:IQV) and Syneos Health (NASDAQ:SYNH) are both business services companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares IQVIA and Syneos Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IQVIA$11.36 billion4.41$279 million$6.0343.38
Syneos Health$4.42 billion2.26$192.79 million$2.8533.79

IQVIA has higher revenue and earnings than Syneos Health. Syneos Health is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IQVIA and Syneos Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IQVIA4.69%23.95%6.03%
Syneos Health4.99%11.35%4.63%

Risk & Volatility

IQVIA has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Syneos Health has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.

Institutional and Insider Ownership

87.0% of IQVIA shares are owned by institutional investors. Comparatively, 97.2% of Syneos Health shares are owned by institutional investors. 1.1% of IQVIA shares are owned by company insiders. Comparatively, 0.3% of Syneos Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for IQVIA and Syneos Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IQVIA011502.94
Syneos Health01602.86

IQVIA currently has a consensus price target of $262.1765, suggesting a potential upside of 0.22%. Syneos Health has a consensus price target of $90.1111, suggesting a potential downside of 6.44%. Given IQVIA's stronger consensus rating and higher possible upside, research analysts plainly believe IQVIA is more favorable than Syneos Health.

Summary

IQVIA beats Syneos Health on 11 of the 14 factors compared between the two stocks.


IQVIA Competitors List

Competitor NameBTM RankShare PriceAnalysts' Price TargetMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Charles River Laboratories International logo
CRL
Charles River Laboratories International
2.1$458.30
-0.7%
$399.83
-12.8%
$23.10 billion$2.92 billion59.0618,400News Coverage
Exact Sciences logo
EXAS
Exact Sciences
2.5$96.02
-2.3%
$151.06
-57.3%
$16.51 billion$1.49 billion-17.595,000
PPD logo
PPD
PPD
1.9$46.85
-0.0%
$44.56
-4.9%
$16.46 billion$4.68 billion65.0726,000Analyst Upgrade
Analyst Revision
Incyte logo
INCY
Incyte
3.1$69.00
-1.1%
$95.38
-38.2%
$15.24 billion$2.67 billion45.401,773Analyst Report
Analyst Revision
News Coverage
ICON Public logo
ICLR
ICON Public
2.1$283.04
-0.6%
$254.50
-10.1%
$14.96 billion$2.80 billion41.5015,730
Syneos Health logo
SYNH
Syneos Health
2.1$96.31
-0.3%
$90.11
-6.4%
$9.97 billion$4.42 billion43.0025,000Positive News
Medpace logo
MEDP
Medpace
2.3$198.21
-1.5%
$190.97
-3.7%
$7.10 billion$925.92 million42.723,600Analyst Upgrade
Anavex Life Sciences logo
AVXL
Anavex Life Sciences
2.0$18.74
-2.9%
$34.00
-81.4%
$1.42 billionN/A-39.0420Analyst Report
News Coverage
ZY
Zymergen
1.2$13.40
-3.0%
$9.83
-26.6%
$1.37 billionN/A0.00758Gap Down
National Research logo
NRC
National Research
1.3$45.16
-1.4%
N/A$1.15 billion$133.28 million32.26485News Coverage
Absci logo
ABSI
Absci
1.7$11.31
-1.3%
$30.00
-165.3%
$1.05 billion$4.78 million0.00N/A
NOTV
Inotiv
2.0$34.32
-1.8%
$40.50
-18.0%
$546.20 million$60.47 million-85.80409Analyst Report
News Coverage
High Trading Volume
SLGC
SomaLogic
0.0$12.77
-0.7%
N/A$440.57 millionN/A0.00N/AHigh Trading Volume
CMII
CM Life Sciences II
0.0$12.77
-0.7%
N/A$352.45 millionN/A0.00N/AHigh Trading Volume
Luna Innovations logo
LUNA
Luna Innovations
2.1$9.81
-0.6%
$14.50
-47.8%
$311.95 million$82.68 million122.64419
Eloxx Pharmaceuticals logo
ELOX
Eloxx Pharmaceuticals
2.0$1.81
-2.2%
$4.03
-122.8%
$156.03 millionN/A-1.6925
LSAQ
LifeSci Acquisition II
0.3$10.00
-0.5%
N/A$100.11 millionN/A0.002
AIkido Pharma logo
AIKI
AIkido Pharma
1.0$0.82
-4.9%
N/A$73.66 million$10,000.00-8.215Gap Down
AIkido Pharma logo
AIKI
AIkido Pharma
1.0$0.82
-4.9%
N/A$73.63 million$10,000.00-8.215High Trading Volume
ISPC
iSpecimen
0.0$6.00
-1.3%
N/A$41.54 millionN/A0.0037News Coverage
This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.